Francois Binette's most recent trade in Renovaro Biosciences Inc was a trade of 65,000 Option to Purchase Common Stock done . Disclosure was reported to the exchange on Feb. 13, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Renovaro Biosciences Inc | Francois Binette | COO and Executive VP for R&D | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 65,000 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Binette Francois | COO and Executive VP for R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 65,000 | 65,000 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Francois Binette | COO and Executive VP for R&D | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 65,000 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Francois Binette | COO and Executive VP for R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 65,000 | 65,000 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Francois Binette | COO and Executive VP for R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 40,000 | 40,000 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Francois Binette | COO and Executive VP for R&D | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 40,000 | 0 | - | - | Option to Purchase Common Stock | |
| Renovaro Biosciences Inc | Francois Binette | Executive VP for R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2022 | 40,000 | 40,000 | - | - | Option to purchase shares of common stock |